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Introduction
Central nervous system (CNS) dissemination has been
reported in 2-10% of diffuse large B-cell lymphoma (DLBCL)
patients.1,2 Although relatively uncommon, it is fatal in over
90% of patients.3,4 Most CNS metastases occur in the setting
of DLBCL relapse and their treatment is mostly palliative.5
The factors most consistently associated with risk of CNS
recurrence are elevated serum lactate dehydrogenase and
involvement of more than one extranodal site.6-9 CNS-direct-
ed prophylactic intrathecal therapy is often used to reduce
the risk of CNS recurrence in these patients but its benefit has
been questioned in recent years.1,10,11 The addition of ritux-
imab to standard cyclophosphamide, doxorubicin, vincristin
and prednisone (CHOP), has improved the outcome of
DLBCL patients,12-16 but the protective effect of rituximab on
CNS recurrence is controversial.2,17-21 Thus, the optimal treat-
ment for CNS dissemination in DLBCL has not yet been
established and new therapies are needed in order to prevent
or treat this fatal condition. However, the lack of appropriate
animal models that reproduce CNS involvement in DLBCL
hinders the development of new drugs. 
Brain metastasis is a multistep process of tumor cell attach-
ment to microvessel endothelial cells, extravasation into the
brain, interaction with the local microenvironment and pro-
liferation. This process involves precise regulation of cell-cell
adhesion and cell-extracellular matrix (ECM) adhesion.22,23
The cell-ECM adhesion is maintained by the focal adhesion
complexes, composed of transmembrane receptors known as
integrins, structural proteins (i.e. vinculin, talin, paxilin) and
signaling proteins (i.e. FAK, p130Cas, HEF1, Pyk2).24 A critical
step in the CNS metastasis process is tumor cell adhesion to
the vascular basement membrane of the brain which is medi-
ated by integrin signaling.25,26 Thus, agents that efficiently
block tumor cell adhesion mediated by focal adhesion signal-
ing in DLBCL may prevent CNS progression.
We recently found that E7123, a novel non-COX-2 celecox-
ib derivative capable of inhibiting focal adhesion signaling,
had in vitro antitumor effect against DLBCL cell lines and
reduced tumor volume in a NOD/SCID subcutaneous model
of DLBCL.27 Our group has also shown that subcutaneous
conditioning of cells prior to intravenous injection of DLBCL
cell lines increased tumor take rate and cell dissemination
capacity as compared to direct intravenous injection in
NOD/SCID mice.28 In this paper, we aimed to evaluate the
therapeutic effect of E7123 in a novel xenograft mouse model
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Central nervous system dissemination is a relatively uncommon but almost always fatal complication in diffuse
large B-cell lymphoma patients. Optimal therapy for central nervous involvement in this malignancy has not been
established. In this paper, we aimed to evaluate the therapeutic effect of E7123, a celecoxib derivative that inhibits
focal adhesion signaling, in a novel xenograft model of diffuse large B-cell lymphoma with central nervous system
involvement. Cells obtained after disaggregation of HT subcutaneous tumors (HT-SC cells) were intravenously
injected in NOD/SCID mice. These mice received oral vehicle or 75 mg/kg of E7123 daily until they were eutha-
nized for weight loss or signs of sickness. The antitumor effect of E7123 was validated in an independent experi-
ment using a bioluminescent mouse model. Intravenously injected HT-SC cells showed higher take rate and higher
central nervous system tropism (associated with increased expression of β1-integrin and p130Cas proteins) than
HT cells. The oral administration of E7123 significantly increased survival time in 2 independent experiments
using mice injected with unmodified or bioluminescent HT-SC cells. We have developed a new xenograft model
of diffuse large B-cell lymphoma with central nervous system involvement that can be used in the pre-clinical eval-
uation of new drugs for this malignancy. E7123 is a new, well-tolerated and orally available therapeutic agent that
merits further investigation since it may improve current management of diffuse large B-cell lymphoma patients
with central nervous system involvement.
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of DLBCL with CNS involvement. The animal model was
generated by performing a subcutaneous passage of HT
cells, which had previously shown CNS tropism after
direct intravenous injection, before their intravenous injec-
tion in NOD/SCID mice. 
Design and Methods 
Cell line and compounds
HT human DLBCL cell line (DMSZ Cell Line Bank) was cul-
tured in RPMI 1640 supplemented with 10% fetal bovine serum,
1% glutamine, 100 units/mL penicillin/streptomycin (Life
Technologies) and incubated at 37ºC in a humidified atmosphere
containing 5% CO2. HT-SC cells or bioluminescent HT-Luc-SC
cells were obtained from HT or HT-Luc subcutaneous tumors,
respectively (see below). E7123 was synthesized by the HSCSP
Pharmacy Department and Laboratories Esteve S.A.
Lentiviral infection of HT cells
A plasmid containing the Luciferase gene (Luc) was constructed
by subcloning and replacing the GFP1 gene of the plasmid pSIN-
DUAL-GFP1-GFP2, kindly provided by Dr Mary Collins (College
Medical School, Cleveland, OH, USA). Luciferase cDNA was
obtained from the plasmid pPK-CMV-F3 (C-Luc) (Promokine,
Heidelberg, Germany). Lentiviral particles containing the pSIN-
DUAL-Luciferase-GFP2 vector, were used to infect HT cells as
described previously by our group.27 Infected cells, termed HT-Luc
cells, were used for in vivo experiments.
Animal experiments
Animal procedures were approved by the Hospital Sant Pau
Animal Ethics Committee according to established guidelines.
NOD/SCID mice were subcutaneously inoculated with HT or
HT-Luc cells. Cells obtained from subcutaneous tumors, HT-SC or
HT-Luc-SC, were intravenously injected in mice to evaluate the
aggressiveness of the subcutaneous conditioning and to evaluate
E7123 antitumor effect. Mice were orally administered with
E7123 (75 mg/kg) or vehicle (PEG:FBS) until they were euthanized
(Online Supplementary Figures S1 and S2). End points were a 15%
loss in body weight or the appearance of motor problems or evi-
dent signs of sickness. In vivo bioluminescence imaging (BLI) was
performed as previously described.29 Dorsal BLI pictures were
taken once a week (ORCA-II Deep Cooling BTW Imaging System,
Hamamatsu Photonics, Hamamatsu City, Japan) and quantified as
described in the Online Supplementary Appendix.
Immunohistochemistry
Paraffin-embedded tissue sections of HT-SC or HT infiltrated
brains were used to detect CD20, CD10, Ki67 (DAKO,
Carpinteria, CA, USA), p130Cas (Neomarkers, Fremont, CA,
USA) and β1-integrin (Upstate, Billerica, MA, USA) proteins.
Immunohistochemical reactions were performed in a DAKO
Autostainer Link48 following the manufacturer’s instructions. All
slides were viewed with an Olympus BX51 microscope. Images
were acquired using an Olympus DP72 digital camera and
processed with the Olympus CellD Imaging 3.3 software
(Olympus Corporation, Tokyo, Japan). 
Western blot analysis
HT-SC cell lysates were used to evaluate protein expression.
Western blots were performed as previously described.30 The fol-
lowing primary anti-human antibodies diluted in TBS-T, contain-
ing 0.1% BSA, were used: mouse anti-p130Cas, anti-AKT, anti-
FAK, anti-FAK Tyr397, anti-Pyk2, anti-Lyn, anti-Mcl1, anti-inte-
grinβ1 (BD Pharmingen, San Jose, CA, USA), rabbit anti-AKT
Thr308 and anti-Src (Cell Signalling, Danvers, MA, USA) and goat
anti-β-actin (Santa Cruz Biothecnology, CA, USA). The secondary
antibodies used were anti-mouse-IgG and anti-rabbit IgG (Jackson
Immunoresearch, West Grove, PA, USA).
Statistical analysis
Differences in survival between control HT or HT-SC groups
and between HT-SC or HT-Luc-SC mice receiving vehicle or drug
were calculated using Kaplan-Meier curves and the log rank test.
Fisher’s exact test was used to calculate differences between cate-
gorical variables. P<0.05 was considered statistically significant.
Further details are described in the Online Supplementary Appendix.
Results
Subcutaneous passage of the HT cell line enhanced
engraftment 
Previous studies revealed that direct intravenous injec-
tion of DLBCL cells in NOD/SCID mice showed ineffi-
cient take rate and took a long time to generate lym-
phoma. However, when we performed a subcutaneous
passage of the same DLBCL cell lines before their intra-
venous injection in mice their aggressiveness was dramat-
ically increased, producing a disseminated lymphoma in
all mice in a short period of time.28 In a preliminary exper-
iment, we observed that direct intravenous injection of
HT cells produced lymphoma in 2 of 10 mice at 66 and 74
days after injection, and that both mice showed CNS infil-
tration. In order to increase the take rate and the aggres-
siveness of these cells, we performed a subcutaneous pas-
sage of HT cells before their intravenous injection, and
compared their take rate and the animal survival with con-
trol mice directly injected with HT cells, without previous
subcutaneous passage (see Design and Methods). Cells
obtained after disaggregation of HT subcutaneous tumors
were named HT-SC cells. In the intravenously injected
HT-SC group, one mouse had to be excluded from the
experiment as a tumor developed in the injection point.
The remaining mice in this group (n=7) were euthanized
between Days 40 and 51 post-injection, when they
reached a 15% weight loss. In contrast, only 2 of 10 HT
control mice were euthanized at Days 78 and 89 after
injection as a consequence of weight loss. The remaining
mice in the HT control group were sacrificed at Day 100
without any sign of disease and histopathological analysis
revealed no tumor development. There was a statistically
significant difference in survival times between groups
(P<0.01) as shown by Kaplan-Meier analysis (Figure 1A).
Interestingly, mice from the experimental HT-SC group
showed a visible cranial inflammation at approximately
Day 30 after injection.
Intravenous injection of HT-SC cells generated DLBCL
in the CNS
Most mice showed motor difficulties (generally circular
motion) before being sacrificed. At necropsy, we observed
that mice from the experimental group showed an evident
cranial inflammation in comparison with mice from the
HT control group (Figure 1B). When analyzed microscop-
ically, we observed that 100% of HT-SC mice showed
brain infiltration, especially in leptomeninges (Figure 2A-
H), whereas only one of 2 infiltrated HT control mice
showed this involvement (Table 1). Infiltrated brains of
the HT-SC mice were positive for CD20 (B-cell antigen)
(Figure 2I) and CD10 (germinal center marker) (Figure 2J)
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immunostaining, confirming that HT-SC cells maintained
the germinal center DLBCL phenotype found in the origi-
nal HT cells. Immunostaining with the proliferation mark-
er Ki67 (Figure 2K) showed a proliferation index of 70-
80% in all lymph nodes, a common proliferation rate in
DLBCL pathology
HT-SC cells showed higher p130Cas and β1-integrin
expression than HT cells
Based on previous evidence showing that in vivo pas-
sages were associated with changes in adhesion proper-
ties,28,31-33 and that the expression of some adhesion mole-
cules could be associated with CNS-tropism,23,25 we stud-
ied the expression of β1-integrin, p130Cas, FAK-P, Pyk2,
Lyn and Src adhesion proteins in HT cell lysates before
(control HT) and after (HT-SC) the subcutaneous passage.
We also assessed other proteins associated with the focal
adhesion pathway, such as Akt-P, Akt and Mcl-1.27 We
detected a marked increase in p130Cas and β1-integrin
expression levels and a slight increase in Src and Mcl-1
expression levels in HT-SC cells as compared to HT cells.
However, there was no alteration in FAK, FAK-P, Akt, Akt-
P, Pyk2 and Lyn proteins during the subcutaneous condi-
tioning of cells (Figure 3A). Immunohistochemistry of β1-
integrin and p130Cas was performed in HT cells before
the subcutaneous passage (HT control), in the subcuta-
neous tumors, in the cells obtained after tumor disaggre-
gation (HT-SC), and in brain tissue sections (Figure 3B).
The intensity of the β1-integrin and p130Cas immunos-
taining was clearly higher in subcutaneous tumors and in
HT-SC cells than in the control HT cells. We also observed
that this high intensity was retained in HT-SC cells at the
brain metastases generated after their intravenous injec-
tion in mice. β1-integrin and p130Cas staining was always
localized in the cytoplasm and membrane in HT cells, sub-
cutaneous tumors, HT-SC cells and infiltrated brains.
E7123 increased survival time in the DLBCL animal
model with CNS involvement
Ten days after intravenous injection of HT-SC cells,
mice were randomly divided into two groups and treated
orally with 75 mg/kg E7123 or vehicle. Mice were treated
every day until they were sacrificed for weight loss or
signs of sickness. We used PEG-400:FBS 3:1 as a vehicle
because it showed no toxicity in healthy mice and permit-
ted the total solubilization of E7123 without changing its
antitumor activity in vitro.27 All mice receiving vehicle were
sacrificed between Days 39 and 48 post-injection.
However, mice receiving E7123 were sacrificed between
43 and 85 days after injection. There was a statistically sig-
nificant difference in survival time between both groups
(P=0.01) as assessed by the log rank test (Table 2). Table 2
also shows the microscopic infiltration of brain, lymph
nodes or bone marrow of all mice. 
E7123 increased survival time in a validation experi-
ment using a bioluminescent mouse model of DLBCL
with CNS infiltration
In order to validate the antitumor effect of E7123 in the
new xenograft model of DLBCL disseminated to the CNS,
we performed the same procedure using bioluminescent
subcutaneously-conditioned HT cells (HT-Luc-SC).
HT-Luc-SC cells were intravenously injected in 20
NOD/SCID mice that were randomly divided into two
groups receiving vehicle or 75 mg/kg E7123. The first CNS
bioluminescent signal was observed in 3 vehicle-treated
and 2 E7123-treated mice on Day 17 post-injection. CNS
bioluminescence was observed in all mice between Days
17 and 57 after cell injection. Figure 4A shows the time
course BLI signal in CNS of representative vehicle and
E7123-treated mice. We could observe that the BLI signal
in the CNS of the vehicle-treated mouse increased faster
than in the E7123-treated mouse. BLI intensity quantifica-
tion curves for both groups are represented in Figure 4B.
Thus, DLBCL cell growth in CNS was delayed in E7123-
treated mice. However, E7123 did not block lymphoma
cell invasion of the CNS since there were no significant
differences in the time of initial detection of CNS BLI sig-
nal between groups. 
E7123 also increased mice survival time in this model
since vehicle-treated mice were killed between 36 and 58
days post-injection, whereas E7123-treated mice were
euthanized between 48 and 91 days post-injection (Figure
4C). Two mice from each group were excluded from the
R. Bosch et al.
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Figure 1. Survival in HT-SC mice is
significantly lower than in control
HT mice. (A) Kaplan-Meier analysis
shows a significant reduction in
survival time in HT-SC (n=7) as
compared to control HT mice
(n=10). P value for the log rank
test was <0.01. (B) Macroscopic
evidence for central nervous sys-
tem involvement of DLBCL in
NOD/SCID mice injected with HT-
SC cells via the tail vein. *The
remaining mice (n=8) were eutha-
nized 95 days after injection with-











































experiment because they did not develop lymphoma.
Details of the histopathological features and clinical evolu-
tion of HT-Luc-SC injected mice are shown in Table 3. 
Therefore, we confirmed that E7123 increased mouse
survival time in a bioluminescent model of DLBCL mice
with CNS infiltration. In addition, as observed in the lumi-
nescent images, E7123 slowed down the growth of lym-
phoma cells within the CNS.
Discussion
In this study, we showed that the oral administration of
a novel focal adhesion inhibitor, E7123, increased survival
of mice with DLBCL involving the CNS. The subcuta-
neous passage of HT cells before their intravenous injec-
tion in NOD/SCID mice allowed us to generate a
xenograft model of DLBCL with CNS involvement that
can be used for evaluation of drugs for this malignancy.
We observed that, during the subcutaneous passage, HT
cells acquired an increased expression level of β1-integrin
and p130Cas proteins. This increased expression was
associated with enhanced aggressiveness and CNS tro-
pism of lymphoma cells. 
The outcome of DLBCL patients with CNS occurrence
is extremely poor and they do not appear to benefit from
current prophylactic protocols.2,9-11 Thus, there is a need to
develop new treatments for this fatal condition. However,
the development of new therapies against this malignancy
is hindered by the lack of appropriate animal models to
evaluate them. Some authors reported xenograft models
of primary CNS lymphoma (PCNSL) performed after
injection of the aggressive Burkitt’s lymphoma cells direct-
ly into the brain,34-37 whereas others generated syngeneic
models of CNS lymphoma after intraocular or intracere-
bral injection of murine lymphoma cells in immunocom-
petent hosts.38,39 An important advantage of the latter
models in respect to xenograft models of CNS lymphoma
using immunodeficient mice is that syngeneic models
E7123 antitumor effect in DLBCL infiltrating CnS
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Table 1. Histopathological features and clinical evolution of NOD/SCID mice after intravenous injection of HT or HT-SC cells. 
Clinical features Control HT HT-SC P
N. of positive mice, n. (%) 2/10 (20) 7/7 (100) 0.002
Survival time (days)1 83.5±7.8 42.9±4.8 <0.001
N. of positive mice with CNS infiltration, n. (%) 1/2 (50) 7/7 (100) 0.222
Meningeal infiltration, n. (%) 1/2 (50) 7/7 (100) 0.222
Parenchymal infiltration, n. (%) 1/2 (50) 4/7 (57) 1.000
N. of positive mice with LN infiltration, n. (%) 0/2 (0) 1/7 (14) 1.000
N. of positive mice with BM infiltration, n. (%) 1/2 (50) 2/7 (29) 1.000
Positive mice are those mice that developed lymphoma. P values were calculated using the log rank test for survival time and Fisher’s exact test for categorical variables. CNS:
central nervous system; LN: lymph node; BM: bone marrow. 1Values represent the mean ± SD. 
Figure 2. Histological and immunohistochemical phenotype of the DLBCL model with CNS involvement.  H&E staining of representative
brains in HT-SC mice. Lymphoma cells infiltrated the leptomeninges in most mice (A-D), reaching the parenchyma in isolated cases (D).
Original magnification x40 and corresponding magnification x400 (E-H). Immunohistochemical analyses of CD20 (I), CD10 (J) and Ki67 (K)
in representative sections of HT-SC infiltrated brains. Original magnification x400. Slides were viewed with an Olympus BX51 microscope.


























allow the study of tumor-induced immunity.40,41 However,
they are technically difficult to perform and they do not
use human DLBCL cells. Here, we generated a rapid
xenograft model of DLBCL with CNS involvement
achieved after a simple intravenous injection of HT-SC
cells in NOD/SCID mice. Cells maintained the typical mor-
phology of DLBCL cells and retained the germinal center
DLBCL marker expression of the original HT cells. Our
model also showed a 100% of meningeal infiltration, the
most typical infiltrating pattern found in DLBCL patients
with CNS involvement.5 Moreover, the new biolumines-
cent model of DLBCL with CNS infiltration complements
currently available murine models since it allows the study
of the mechanisms of entrance, migration and growth of
DLBCL cells in the CNS and their inhibition by drugs. 
HT-SC cells used to generate this xenograft model
showed higher levels of β1-integrin and p130Cas expres-
sion than HT cells. It has recently been reported that β1-
integrin interaction with brain vessels is sufficient to pro-
mote proliferation and metastasis within the brain in carci-
nomas and lymphomas.25,26,42 Moreover, p130Cas overex-
pression is associated with metastases in different cancer
R. Bosch et al.
1246 haematologica | 2013; 98(8)
Figure 3. Expression of p130Cas and β1-integrin in HT and HT-SC cells. (A) Immunoblotting of FAK (Tyr 397), FAK, β1-integrin, p130Cas, Pyk2,
Lyn, AKT (Thr 308) and AKT in protein extracts of control HT or HT-SC cells one day (HT-SC1) or seven days (HT-SC7) after disaggregation of
subcutaneous tumors. WSU cell line lysate was used as positive control. HT-SC protein extracts showed higher expression levels of β1-inte-
grin and p130cas than HT control cells. Equal loading was checked by immunobotting with β-actin. (B) Immunostaining analysis of p130Cas
and β1-integrin in control HT cells, HT subcutaneous tumor, HT-SC cells (original magnification x400) and HT-SC infiltrated brain sections
(original magnification x100, inset x400). Slides were viewed with an Olympus BX51 microscope. Images were acquired using an Olympus
DP72 digital camera and processed with the Olympus CellD Imaging 3.3 software.
Table 2. Histopathological features and clinical evolution of HT-SC injected NOD/SCID mice after administration of vehicle or E7123.
Clinical features Vehicle E7123 P
N. of positive mice, n. (%) 7/7 (100) 9/9 (100) -
Survival time (days)1 42.9±4.8 61.1±15.4 0.001
N. of positive mice with CNS infiltration, n. (%) 7/7 (100) 9/9 (100) -
Meningeal infiltration, n. (%) 7/7 (100) 9/9 (100) -
Parenchymal infiltration, n. (%) 4/7 (57) 7/9 (78) 0.596
N. of positive mice with LN infiltration, n. (%) 1/7 (14) 2/9 (22) 1.000
N. of positive mice with BM infiltration, n. (%) 2/7 (29) 2/9 (22) 1.000
Positive mice are those that developed lymphoma. P values were calculated using the log rank test for survival time and Fisher’s exact test for categorical variables. CNS: central

























































types.43,44 β1-integrin and p130Cas are components of the
same signaling pathway which is associated with tumor
invasion.45 Thus, the high β1-integrin and p130Cas expres-
sion levels observed in HT-SC cells could partly explain the
higher aggressiveness and capacity to migrate and grow
into the CNS of DLBCL lymphoma cells as compared to
HT cells. However, further functional studies are needed to
determine whether β1-integrin and/or p130Cas are respon-
sible for HT-SC cells tropism to the CNS and/or growth
into the brain. In a previous study, the non-COX2 inhibitor
celecoxib derivative E7123 showed an in vitro antitumor
effect in different DLBCL cell lines by deregulation of focal
adhesion proteins, which were expressed in the majority
of human DLBCL patient samples. The oral administration
of E7123 was well tolerated and reduced tumor growth in
a subcutaneous xenograft of DLBCL.27 In this paper, we
showed that the focal adhesion inhibitor E7123 increases
mice survival time in 2 independent experiments using a
new xenograft model of DLBCL with CNS involvement.
BLI images confirmed that E7123 did not block the CNS
invasion, but delayed the growth of the DLBCL cells once
in the brain, suggesting that E7123 may be capable of
E7123 antitumor effect in DLBCL infiltrating CnS
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Figure 4. E7123 antitumor effect in an independent experiment using a bioluminescent model of DLBCL with CNS involvement. (A)
Representative BLI images showing lymphoma HT-Luc-Sc cell growth evolution in the CNS in vehicle (PEG:FBS) or treated groups (75 mg/kg
E7123). Vehicle-treated and E7123-treated mice were sacrificed on Days 56 and 92 post-injection of cells, respectively. Arbitrary color bars
illustrate relative light intensity levels from firefly luciferase, ranging from low (blue) to high (red). Corresponding grayscale photographs and
bioluminescent images were superimposed for each animal. (B) BLI signal quantification curves in the CNS for vehicle and E7123-treated
mice. At week 6 after tumor cell injection, one vehicle-treated mouse could not be evaluated for BLI because it showed signs of sickness
that precluded the use of anesthesia. BLI signal was quantified and expressed as Photon Counts (PHC). Curves represent the kinetics of BLI
intensity mean for each group. Error bars represent the standard error. (C) Survival time in HT-Luc-SC mice treated with E7123 (75 mg/kg)
was significantly higher than in control mice (PEG:FBS). P value for the log rank test was <0.01. Kaplan-Meier analysis showed the significant
increase in survival time in treated mice (n=8) as compared to control mice (n=7).  
Table 3. Histopathological features and clinical evolution of HT-Luc-SC injected NOD/SCID mice after administration of vehicle or E7123.
Clinical features Vehicle E7123 P
N. of positive mice, n. (%) 8/10 (80) 8/10 (80) -
N. of positive mice with CNS infiltration, n. (%) 7/8 (87.5) 8/8 (100) 1.000
Meningeal infiltration, n. (%) 7/7 (100) 8/8 (100) -
Parenchymal infiltration, n. (%) 5/7 (71.4) 7/8 (87.5) 0.596
N. of positive mice with LN infiltration, n. (%) 0/8 (0) 2/8 (25) 0.471
N. of positive mice with BM infiltration, n. (%) 1/8 (12.5) 2/8 (25) 1.000
Survival time (days)1 of CNS positive mice 50.1±8.3 74±14.8 0.009
Positive mice are those that developed lymphoma. p values were calculated using the log rank test for survival time and Fisher’s exact test for categorical variables. CNS: central
nervous system; LN: lymph node; BM: bone marrow. 1Values represent the mean ± SD. 
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crossing the blood-brain barrier. Most drugs included in the
standard therapy for DLBCL, CHOP-R, do not reach the
CNS11,20 and, consequently, do not prevent CNS relapse.
Interestingly, E7123 parent compound, celecoxib, crossed
the blood-brain barrier46 and prolonged mice survival time
in a xenograft model of PCNSL.36 The clinical use of cele-
coxib, however, is associated with risk of cardiovascular
events associated with COX-2 inhibition.47 E7123, in con-
trast, does not inhibit COX-2. Thus, E7123 is likely to be
effective for the treatment of CNS relapse in DLBCL with-
out showing cardiovascular toxicity. Considering the
unproven efficacy of current drugs in CNS relapse treat-
ment, and the physical discomfort associated with
intrathecal administration, orally available E7123 could be
an alternative treatment in combination with current ther-
apy to treat CNS involvement in DLBCL in the future.
In conclusion, E7123 is a new, well tolerated and orally
bioavailable therapeutic agent that increases survival time
in a novel xenograft model of DLBCL with CNS involve-
ment. We believe E7123 merits further investigation, as
findings to date suggest it may improve current manage-
ment and Quality of Life of DLBCL patients with this fatal
condition.
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